SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Location
777 W 41 St St, Suite 401, Miami Beach, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 221 % -46.7%
Debt-to-equity 72.6 % +68.2%
Return On Equity -154 % -63.7%
Return On Assets -89.2 % -35.7%
Operating Margin -1.65K % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.4M shares +12.8%
Common Stock, Shares, Outstanding 9.29M shares +0.68%
Entity Public Float 19.5M USD -36.4%
Common Stock, Value, Issued 936 USD +0.75%
Weighted Average Number of Shares Outstanding, Basic 9.29M shares +0.43%
Weighted Average Number of Shares Outstanding, Diluted 9.29M shares +0.43%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.78M USD -56.7%
Research and Development Expense 29.9M USD +28.6%
General and Administrative Expense 12M USD -52.5%
Operating Income (Loss) -41.8M USD +8.66%
Nonoperating Income (Expense) 4.77M USD -12.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.6M USD -67.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -37.1M USD +8.1%
Earnings Per Share, Basic -4 USD/shares +35%
Earnings Per Share, Diluted -4 USD/shares +35%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.69M USD -78.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 9.31M USD -76.5%
Property, Plant and Equipment, Net 13.9M USD -18.1%
Operating Lease, Right-of-Use Asset 3.01M USD +142%
Assets 30.1M USD -51.3%
Accounts Payable, Current 2.62M USD +124%
Employee-related Liabilities, Current 5.09M USD +79.2%
Liabilities, Current 10.7M USD +41.4%
Operating Lease, Liability, Noncurrent 2.26M USD +188%
Liabilities 18.1M USD +14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -15.8K USD +49.6%
Retained Earnings (Accumulated Deficit) -139M USD -36.2%
Stockholders' Equity Attributable to Parent 12M USD -73.9%
Liabilities and Equity 30.1M USD -51.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.8M USD +27.5%
Net Cash Provided by (Used in) Financing Activities -174K USD +55.9%
Net Cash Provided by (Used in) Investing Activities 4.67M USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 9.35M shares +0.67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.26M USD +92.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 70K USD +5.82%
Deferred Tax Assets, Valuation Allowance 27.9M USD +44.9%
Deferred Tax Assets, Gross 29.7M USD +34.6%
Operating Lease, Liability 3.07M USD +147%
Payments to Acquire Property, Plant, and Equipment 129K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37M USD +8.21%
Lessee, Operating Lease, Liability, to be Paid 3.68M USD +166%
Property, Plant and Equipment, Gross 29.9M USD +0.35%
Operating Lease, Liability, Current 815K USD +77.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 713K USD +81.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.01M USD +123%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +25.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 615K USD +319%
Lessee, Operating Lease, Liability, to be Paid, Year Three 729K USD +740%
Deferred Tax Assets, Operating Loss Carryforwards 14.7M USD +42.9%
Preferred Stock, Shares Issued 42K shares -0.51%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 709K USD +686%
Operating Lease, Payments 799K USD -4.99%
Additional Paid in Capital 157M USD +1.91%
Preferred Stock, Shares Outstanding 42K shares -0.51%
Depreciation, Depletion and Amortization 3.3M USD -31.5%
Deferred Tax Assets, Net of Valuation Allowance 1.87M USD -34.6%
Share-based Payment Arrangement, Expense 2.96M USD +23.7%
Interest Expense 317K USD -2.75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%